BridgeBio Pharma (NASDAQ:BBIO) Stock Unloaded by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in BridgeBio Pharma stock on September 29th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Alkermes (NASDAQ:ALKS) on 9/29/2026.

BridgeBio Pharma Stock Performance

BBIO opened at $64.94 on Thursday. The business has a 50 day moving average price of $73.43 and a 200 day moving average price of $73.39. BridgeBio Pharma, Inc. has a twelve month low of $52.75 and a twelve month high of $93.42.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million for the quarter, compared to the consensus estimate of $220.91 million. The firm’s revenue for the quarter was up 120.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.95) earnings per share. On average, research analysts expect that BridgeBio Pharma, Inc. will post -2.62 earnings per share for the current fiscal year.

Insider Activity

In other BridgeBio Pharma news, CAO Maricel Apuli sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $80.06, for a total value of $160,120.00. Following the completion of the sale, the chief accounting officer owned 127,401 shares in the company, valued at approximately $10,199,724.06. This trade represents a 1.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 34,980 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $82.53, for a total value of $2,886,899.40. Following the sale, the chief executive officer directly owned 243,327 shares in the company, valued at $20,081,777.31. The trade was a 12.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 56,980 shares of company stock worth $4,578,119 over the last 90 days. Corporate insiders own 14.23% of the company’s stock.

Wall Street Analyst Weigh In

BBIO has been the subject of a number of research analyst reports. Morgan Stanley cut their target price on shares of BridgeBio Pharma from $98.00 to $97.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Barclays lowered their price target on BridgeBio Pharma from $157.00 to $156.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 7th. Citigroup raised their price target on BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. JPMorgan Chase & Co. lifted their price objective on BridgeBio Pharma from $100.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. Twenty-one investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $104.75.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hsbc Holdings PLC raised its position in shares of BridgeBio Pharma by 139.4% during the first quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock valued at $2,431,000 after buying an additional 19,043 shares during the last quarter. Assetmark Inc. lifted its stake in shares of BridgeBio Pharma by 423.7% in the first quarter. Assetmark Inc. now owns 20,790 shares of the company’s stock valued at $1,544,000 after buying an additional 16,820 shares during the period. Corient Private Wealth LP acquired a new stake in BridgeBio Pharma during the second quarter worth about $1,783,000. Squarepoint Ops LLC grew its position in BridgeBio Pharma by 114.2% during the second quarter. Squarepoint Ops LLC now owns 1,191,732 shares of the company’s stock worth $88,760,000 after buying an additional 635,408 shares in the last quarter. Finally, EFG International AG acquired a new stake in BridgeBio Pharma during the second quarter worth about $6,117,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a biotechnology company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company uses its drug discovery and development platform to advance therapies across areas including rare diseases, genetic disorders and precision oncology, with programs designed to address the underlying biological causes of disease.

BridgeBio operates through a collection of subsidiary companies and development programs. Its portfolio has included therapies for cardiovascular, endocrine, neurological and oncological conditions.